News for IRME Stock

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S. Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16 IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024 IR-MED Appoints Richard Serbin, Esq. to its Advisory Board IR-MED Chairman & Interim CEO Issues Letter to Shareholders IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device IR-Med’s PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium IR-Med to present at National Pressure Injury Advisory Panel 2023 IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY IR-Med Gains Momentum in 2022 IR-Med Announces Dr. David Dalton as Advisory Board member IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries IR-Med To Initiate Useability Study of its PressureSafe Device IR-MED Names Moshe Gerber as New CEO IR-Med Announces $3.2 Million Private Placement Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company” IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB IRME Letter to Shareholders IR-Med to Become Fully Reporting SEC Company IR-Med, Inc. Announces the Appointment of Dr. Rom Eliaz as Chief Executive Officer IR-Med, Inc. Announces the Resignation of Limor Davidson Mund as CEO and Appointment of Chairman of the Board Oded Bashan as Interim Chief Executive Officer